KR102202224B1 - A composition for the prevention or treatment of depression comprising herb extract YJ06 - Google Patents

Abstract

The present invention relates to a composition for improving, preventing or treating depressive symptoms. By containing a mixed extract consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient, depressive symptoms can be improved, prevented or treated. In addition, since it is not toxic, it can be consumed in the form of food.

Description

A composition for the prevention or treatment of depression comprising herb extract YJ06}

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms by containing a mixed extract (referred to as YJ06) consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam.

Depressive symptoms, called modern epidemics, are emerging as a particularly serious social problem in Korea, resulting in increased social and economic costs, and a national concern. The causes of the depressive symptoms vary, but stress is considered an important cause.

The depressive symptoms are not only indicative of emotional disorders, but also in cognitive and physical physiological symptoms. Specifically, depressive symptoms cause emotional symptoms such as mood disorders in which depression, sadness, and the like last a long time; It not only causes cognitive symptoms such as decreased cognitive function such as attention, memory, judgment, guilt delusion, self-deprecation, damage delusion, and pessimistic thoughts; It causes body physiological symptoms such as changes in weight and appetite (excessive, underrepresented), decreased vitality and vitality, severe fatigue, sleep disturbances (insomnia or excessive sleep), indigestion, headache, and decreased immunity.

The depressive symptoms can be largely caused by genetic factors and environmental factors such as stress. The detailed mechanisms accompanying these causes include the reduction of neurotransmitters such as dopamine and serotonin, the decrease in the expression of neurotrophic factors, and the decrease in the generation of new neurons related to this, and the expression of key genes in the nervous system in the long term due to the influence of epigenetic mechanisms. Inhibition or increase, changes in energy metabolism of nerve cells, damage to nerve cells due to accumulation of oxidative stress, etc. have been suggested.

As described above, the fact that the causes of depressive symptoms are diverse means that a method of preventing or treating depressive symptoms needs to be developed accordingly.

Currently, treatments for depressive symptoms used in clinical practice are generally developed and tested through animal models of depressive symptoms. All treatments for depressive symptoms are understood to have a drug action that enhances drug action at synapses by inhibiting the decomposition and reabsorption of monoamines such as dopamine, serotonin, and noepinephrine, which are neurotransmitters between brain neurons. However, since the drug has a large difference in efficacy depending on the patient, it is necessary to develop a new antidepressant that supplements or replaces this problem.

According to the statistics on the treatment of depressive symptoms recently released by the National Health Insurance Service, the number of depressed patients increased by 12.4% in 2011 compared to 2007. In 2009-2010, suicide caused by mental and psychiatric problems is the cause of suicide. It ranks first, and the number of people who committed suicide as a cause of this is increasing to 4,132 (28.1%) in 2009 and 4,357 (29.5%) in 2010. In addition to depression, attention deficit/hyperactivity disorder (ADHD) patients also increased from 48,000 in 2007 to 57,000 in 2012, an increase of 9,000 for five years, and an average annual increase of 4.4%. .

Therefore, it is possible to quickly improve, prevent or treat depressive symptoms, and there is a need for extracts from natural herbal medicines that are stable and have no side effects.

Republic of Korea Patent Publication No. 2014-0062958 Republic of Korea Patent Publication No. 2013-0000817 Korean Patent Registration No. 1010370

An object of the present invention is to provide a pharmaceutical composition for improving, preventing or treating depressive symptoms containing a mixed extract (YJ06) consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient.

In addition, another object of the present invention is to provide a food composition for preventing or improving pain containing a mixed extract (YJ06) consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient.

A pharmaceutical composition capable of preventing or treating depressive symptoms of the present invention for achieving the above object may contain a mixed extract consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient.

The Mokdanpi, Baekbokryeong, Taeksa, and Dansam may be mixed in a weight ratio of 1: 0.5-2: 0.5-2: 0.5-2, preferably 1: 1: 1: 1.

The mixed extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof.

In addition, the food composition capable of preventing or improving the depressive symptoms of the present invention for achieving the other objects described above may contain a mixed extract consisting of mokdanpi, baekbokryeong, taeksa and dansam as an active ingredient.

The composition capable of improving, preventing or treating depressive symptoms containing a mixed extract consisting of Mokdanpi, Baekbokryong, Taeksa and Dansam as an active ingredient of the present invention is not toxic, and has excellent improvement, prevention or treatment effects on depressive symptoms, and is competitive. It is effective in the manufacture of food compositions and pharmaceutical compositions.

1 is a photograph showing the movement of an animal for analysis when a forced swimming experiment is performed to measure depressive symptoms.

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms by containing a mixed extract (YJ06) consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam.

Hereinafter, the present invention will be described in detail.

The composition capable of improving, preventing or treating depressive symptoms of the present invention contains a mixed extract consisting of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient.

Paeonia suffruticosa has a peculiar smell, a bit bitter taste, and a little cold in nature, and pain relief , soothing, antipyretic, anticonvulsant, anti-inflammatory, antithrombotic, antiallergic, gastric secretion inhibition, uterine mucosa congestion, antibacterial Actions and the like have been reported.

In addition, the Baekbokryung ( Poria cocos ) has been found to have a diuretic effect, lowering blood sugar levels, and sedation, and is also known to have an immune reactivation effect.

In addition, Alisma orientale is a perennial herbaceous plant belonging to the family Taeksa family.渴), diabetes, high blood pressure, fat, liver and other symptoms.

In addition, Salvia miltiorrhiza is a perennial herbaceous plant belonging to the Lamiaceae family, and is effective in antibacterial action, menstrual pain, menstrual impurities and postpartum lower abdominal pain, chronic hepatitis, liver dysfunction, and early symptoms of cirrhosis.

The Mokdanpi, Baekbokryeong, Taeksa and Dansam are mixed in a weight ratio of 1: 0.5-2: 0.5-2: 0.5-2, preferably 1: 1: 1: 1.

If the content of Baekbokryeong, Taeksa, and Dansam is less than the lower limit of Mokdanpi, the effect of improving, preventing or treating depressive symptoms may be lower than that of using each herbal medicine alone. The effect of improving, preventing or treating may be diminished.

When the Mokdanpi, Baekbokryeong, Taeksa, and Dansam are used alone, the efficacy is 1.5 to 20 times lower than that of Mokdanpi, Baekbokryeong, Taeksa and Dansam.

The mixture of Mokdanpi, Baekbokryeong, Taeksa and Dansam is mixed with an extraction solvent in a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, extracted at 90 to 110°C, and concentrated under reduced pressure at 50 to 60°C. Prepare the extract. When the weight ratio of the mixture of Mokdanpi, Baekbokryeong, Taeksa and Dansam and the extraction solvent is out of the above range, the active ingredient of the mixture of Mokdanpi, Baekbokryeong, Taeksa and Dansam in the extract may be extracted in a small amount.

The extraction solvent for extracting each extract is water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The extraction solvent is not particularly limited, but the extract extracted with water works preferably for improvement, prevention or treatment of depressive symptoms.

In the present specification, the term'extract' used while referring to a mixture of Mokdanpi, Baekbokryeong, Taeksa and Dansam includes not only crude extract obtained by treatment with an extraction solvent, but also a processed product of a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam. For example, the mixed extract of Mokdanpi, Baekbokryeong, Taeksa, and Dansam may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

In addition, the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam of the present invention is a mixed processed product of Mokdanpi, Baekbokryeong, Taeksa and Dansam, formulated to administer a mixture of Mokdanpi, Baekbokryeong, Taeksa and Dansam in a broad sense, such as , Mokdanpi, Baekbokryeong, Taeksa and Dansam mixed powders are also meant to be included. Although the experiment was conducted with a mixture of Mokdanpi, Baekbokryeong, Taeksa, and Dansam in the present invention, it will be expected by those skilled in the art that the desired effect can be achieved even in the form of a mixed processed product of Mokdanpi, Baekbokryeong, Taeksa and Dansam.

Meanwhile, in the present specification, the term "contained as an active ingredient" means including an amount sufficient to achieve the efficacy or activity of the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam. For example, the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam is used at a concentration of 10 to 1500 µg/ml, preferably 100 to 1000 µg/ml. Since the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam is a natural product and does not have side effects on the human body even if it is administered in excessive amounts, the upper limit of the quantity of the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam contained in the composition of the present invention is selected within an appropriate range It can be done.

The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes excipients, disintegrants, sweeteners, binders, coating agents, expanding agents, lubricants, It is possible to use a lubricant or flavoring agent.

For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.

The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, lacquercanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.

Furthermore, it can be preferably formulated according to each disease or ingredient using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .

A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, Usually, the skilled practitioner can readily determine and prescribe the dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.

The pharmaceutical composition of the present invention may be prepared in a unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient, or may be prepared by placing it in a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.

In addition, the present invention provides a food composition for improving, preventing or treating depressive symptoms containing a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient.

The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, health supplements. Etc.

The food composition of the present invention may include mixed extracts of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient, as well as ingredients commonly added during food production, for example, protein, carbohydrate, fat, nutrients, seasoning And flavoring agents. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts, etc., in addition to the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam of the present invention. May be additionally included.

The present invention provides a health functional food comprising a food composition for improving, preventing or treating depressive symptoms comprising a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient. Health functional foods are foods prepared by adding mixed extracts of Mokdanpi, Baekbokryong, Taeksa, and Dansam to food ingredients such as beverages, teas, spices, gums, confectionery, etc., or prepared as encapsulated, powdered, suspension, etc. It means bringing a specific effect on health, but unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of mixed extract of Mokdanpi, Baekbokryeong, Taeksa, and Dansam in such health functional foods cannot be uniformly regulated depending on the type of health functional food to be targeted, but if added within the range that does not damage the original taste of the food And, it is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight, based on the target food. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

In addition, the present invention provides a use of a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam for the manufacture of medicines or foods for improving, preventing or treating depressive symptoms. As described above, the mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam may be used for improving, preventing or treating depressive symptoms.

In addition, the present invention provides a method for improving, preventing or treating depressive symptoms, comprising administering an effective amount of a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam to a mammal.

The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, and preferably refers to a human.

The term "effective amount" as used herein refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, which is considered by a researcher, veterinarian, doctor or other clinician, Includes an amount that induces relief of symptoms of the disease or disorder. The effective amount and the number of administrations for the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, and general health of the patient. It can be adjusted according to various factors including condition, sex and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used simultaneously. In the prevention, treatment or improvement method of the present invention, in the case of an adult, when a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam is administered once to several times a day, it is administered at a dose of 0.001 g/kg to 10 g/kg. It is desirable.

In the treatment method of the present invention, a composition comprising a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam as an active ingredient is oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or It can be administered in a conventional manner via the intradermal route.

Hereinafter, a preferred embodiment is presented to aid the understanding of the present invention, but the following examples are only illustrative of the present invention, and it is obvious to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention, It is natural that such modifications and modifications fall within the appended claims.

Example 1.Mokdanpi: Baekbokryeong:Taeksa: Dansam = 1:1:1:1 by weight

After mixing Mokdanpi, Baekbokryeong, Taeksa, and Dansam purchased from Han Kook Shin Yak Pharmaceutical Co., Ltd., Nonsan, Korea in a weight ratio of 1:1, the mixture and water are 1: The mixture was mixed at a weight ratio of 10 and extracted with hot water at 100° C. for 3 hours to obtain a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam.

Example 2. Mokdanpi: Baekbokryeong:Taeksa: Dansam = 1:1.5:1:1.5 weight ratio

In the same manner as in Example 1, Mokdanpi, Baekbokryeong, Taeksa and Dansam were mixed in a weight ratio of 1:1.5:1:1.5 to obtain a mixed extract.

<Test Example>

Prepared in Examples and Comparative Examples After filtering the extract, the filtrate was concentrated under reduced pressure at 60° C. or lower and used.

250-300 g of Wistar rats (25-25 g of ICR mice) (SAMTAKO, Korea, male) were used in the experiment. It was bred in an acrylic cage (45 X 60 X 25 cm), provided with sufficient feed and water, and controlled the day and night for 12 hours with appropriate artificial illumination (from 8:00 am to daytime). And it maintained a constant temperature (20 ~ 24 ℃) and humidity (45 ~ 65%). They looked for a week to adapt to the changed environment, maintained the sleep cycle, and confirmed abnormal behavior.

All experiments using animals comply with MFDS's (Ministry of Food and Drug Safety) National Institute of Toxicological Research for the care and use of laboratory animals (KHUASP(SE)-14-051), and the experimental method was conducted by Daejeon University Animal Experimental Ethics Committee. Approved.

Experimental animals were selected only healthy animals with a constant body weight change, the normal group administered with physiological saline by a random batch method, the control group administered with reserpine, and the group administered with reserpine. Example 1 And the sample administration group to which the extract of 2 was administered, and 5 mice were used for the normal group and the control group 1, and 5 mice were used for the control group 2 and the remaining groups.

At this time, reserpine was administered by injection of 1 mg/kg at a certain time once a day for 7 days, and the extracts of Examples 1 and 2 were in saline at the following concentrations (100, 200, 300 mg/kg). It was dissolved and administered orally 100 ul.

-8 groups of mice-

Normal group: physiological saline solution administered for 7 days_1 mg/kg/day

Control 1: Reserpine 7 day administration_1 mg/kg/day

Control 2: Reserpine 7-day administration_1 mg/kg/day + fluoxetine_50 mg/kg (intraperitoneal administration)

Example 1 (100): 7-day administration of reserpine_1 mg/kg/day + 100 mg/kg of extract of Example 1

Example 1 (200): 7-day administration of reserpine_1 mg/kg/day + 200 mg/kg of extract of Example 1

Example 1 (300): 7-day administration of reserpine_1 mg/kg/day + 300 mg/kg of extract of Example 1

Example 2 (100): 7-day administration of reserpine_1 mg/kg/day + 100 mg/kg of extract of Example 2

Example 2 (200): 7-day administration of reserpin_1 mg/kg/day + 200 mg/kg of extract of Example 2

Example 2 (300): 7-day administration of reserpine_1 mg/kg/day + 300 mg/kg of extract of Example 2

Test Example 1. Weight measurement

Weight change was measured to confirm loss of appetite, one of the symptoms of depression. Body weight was measured once every day at the same time during the experiment.

[Table 1]

As shown in Table 1 above, it was confirmed that the extract prepared according to Example 1 of the present invention did not show weight loss, which is one of the serious injuries of depression. That is, even when the extract of Example 1 is administered at a high concentration, weight loss does not appear, which means that there is no side effect due to the high concentration.

On the other hand, it was confirmed that the extract prepared according to Example 2 exhibited weight loss and showed symptoms such as weak diarrhea and hair loss.

Test Example 2. Antidepressant verification_Forced swimming test

Through the forced swimming experiment, an antidepressant experiment on evasion ability in emergency situations was performed from a behavioral pharmacological perspective.

For the FST measurement method of mice, a transparent beaker having a height of 50 cm or more was filled with water by 30 cm, and after 1 hour, the mice were acquired and recorded using a video recorder for 6 minutes. The recorded result was measured for the remaining 5 minutes except for the first 1 minute, the time the mouse remains still without movement (immobility time, sec, the state in which the mouse is suspended on the surface without any movement). Animal movements were analyzed by dividing into swimming (swimming), climbing (climbing), and immobility/floating positions, respectively (FIG. 1).

All experimental results were obtained from S.E.M. It is expressed as a value, and one-way ANOVA statistical processing is performed by the bonferroni post-hoc method using Prism 5.0 (GraphPad software, Inc., USA). Treatment was allowed within the range of statistically significant p<0.05.

[Table 2]

As shown in Table 2 above, it was confirmed that the extract prepared according to Example 1 of the present invention significantly reduced the immobility time compared to the group to which reserpine was administered.

On the other hand, the extract prepared according to Example 2 showed little decrease in immobility time, but only in the group administered 200 mg/kg.

That is, it was confirmed that the immobility time of the extract prepared according to Example 1 was reduced compared to the extract of Example 2.

This means that the extracts of Examples 1 and 2 are effective against antidepressant, and furthermore, all extracts of Example 1 are effective against antidepressant compared to the 200 mg/kg extract of Example 2.

Test Example 3. Antidepressant Verification_Open-field Test

As a simple test to observe the movement of the mouse, it is an experiment to observe the movement of the mouse by placing it in a rectangular box without a lid of any size. It is used as a measure of depression related to fear or anxiety by comparing and analyzing the increase or decrease of the movement distance or the number of crossings within a certain space.

[Table 3]

[Table 4]

As shown in Tables 3 and 4 above, it was confirmed that the extract prepared according to Example 1 of the present invention increased the travel distance significantly compared to the group to which reserpine was administered, and Example 2 showed significant movement in all extracts. There was no effect of increasing the distance.

It was separately confirmed that the travel distance of the extract prepared according to Example 1 increased a lot compared to the extract of Example 2.

This means that the extracts of Examples 1 and 2 are effective for antidepressant, and furthermore, the extract of Example 1 is effective for antidepressant compared to the extract of Example 2.

Test Example 4. Analgesic effect measurement

A physical allodynia experiment was performed 30 minutes after oral administration, and the physical allodynia refers to a reaction to feel pain when a weak stimulus is applied that only causes a simple tactile reaction without causing pain in a healthy state (Fig. 1). . Animals were placed in cages with wire floors for the measurement of mechanical allodynia. The withdrawal threshold was measured in ipsilateral and/or contralateral hind paws by electronic von Frey filament (Somedic AB, Malmo, Sweden). The median of the 5 stimuli provided the data points. The half-maximal effective amount (ED50) with the corresponding 95% confidence limit was determined by semi-logarithmic regression analysis at maximum action.

The degree of analgesia was indicated by the area under the curve obtained (MA area under the curve).

[Table 5]

As shown in Table 5 above, it was confirmed that the extract prepared according to Example 2 had an analgesic effect on significant neuropathic pain at all concentrations.

On the other hand, it was confirmed that the extract of Example 1 exhibited an analgesic effect on neuropathic pain only when 300 mg/kg was administered.

As a result, it is judged that the extract of Example 1 shows an even effect on depression and pain without side effects from administration, while the extract of Example 2 shows a slight side effect and shows higher efficacy in pain than depression.

The pain is a pain caused by administration of reserpine, and may be specifically fibromyal pain.

Hereinafter, examples of the formulation of the composition containing the powder of the present invention will be described, but the present invention is not intended to limit this, but is intended to be described in detail.

Formulation Example 1. Preparation of powder

500 mg of extract powder obtained in Example 1

100 mg lactose

10 mg of talc

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2. Preparation of tablet

300 mg of extract powder obtained in Example 1

100 mg corn starch

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet preparation method.

Formulation Example 3. Preparation of Capsule

200 mg of extract powder obtained in Example 1

3 mg of crystalline cellulose

14.8 mg lactose

Magnesium stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.

Formulation Example 4. Preparation of injection

600 mg of extract powder obtained in Example 1

Mannitol 180 mg

2974 mg of sterile distilled water for injection

Na ₂ HPO _4, 12H ₂ O 26 mg

It is prepared with the above ingredients per ampoule according to a conventional injection preparation method.

Formulation Example 5. Preparation of liquid formulation

4 g of extract powder obtained in Example 1

10 g of isomerized sugar

5 g of mannitol

Purified water appropriate amount

According to the usual preparation method of liquid preparation, add each ingredient to purified water to dissolve it, add lemon zest, mix the above ingredients, add purified water and add purified water to adjust the total to 100g, then fill in a brown bottle for sterilization. To prepare a solution.

Formulation Example 6. Preparation of granules

1,000 mg of extract powder obtained in Example 1

Vitamin mixture right amount

Vitamin A acetate 70 ㎍

1.0 mg of vitamin E

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

0.5 mg of vitamin B6

Vitamin B12 0.2 ㎍

Vitamin C 10 mg

Biotin 10 ㎍

1.7 mg of nicotinic acid amide

Folic acid 50 ㎍

0.5 mg of calcium pantothenate

Suitable amount of inorganic mixture

1.75 mg ferrous sulfate

Zinc oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dicalcium phosphate 55 mg

90 mg of potassium citrate

100 mg of calcium carbonate

Magnesium chloride 24.8 mg

The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And can be used to prepare a health functional food composition according to a conventional method.

Formulation Example 7. Preparation of functional beverage

1,000 mg of extract powder obtained in Example 1

1,000 mg citric acid

100 g oligosaccharides

2 g of plum concentrate

1 g taurine

Total 900 mL with purified water

After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating the mixture at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and stored in a refrigerator. It is used to prepare the functional beverage composition of the invention.

The composition ratio is composed of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as the demand class, the country of demand, and the purpose of use.

Claims (6)

A pharmaceutical composition for preventing or treating depressive symptoms, characterized in that it contains a mixed extract extracted with hot water by mixing Mokdanpi, Baekbokryeong, Taeksa and Dansam in a weight ratio of 1: 0.5-2: 0.5-2: 0.5-2 as an active ingredient. delete The pharmaceutical composition for preventing or treating depressive symptoms according to claim 1, wherein the Mokdanpi, Baekbokryeong, Taeksa and Dansam are mixed at a weight ratio of 1:1:1:1. delete A food composition for preventing or improving depressive symptoms, characterized in that it contains a mixed extract extracted with hot water by mixing Mokdanpi, Baekbokryeong, Taeksa and Dansam in a weight ratio of 1: 0.5-2: 0.5-2: 0.5-2 as an active ingredient. delete

Images